Nicole Lamanna, MD

Articles by Nicole Lamanna, MD

CLL Trial Insights: Targeted Therapy Risks and Outcomes

Nicole Lamanna, MDChronic Lymphocytic Leukemia | July 3, 2025

BTK inhibitor safety: New analysis shows less hypertension risk with acalabrutinib or zanubrutinib vs ibrutinib in CLL.

What Is the Best Strategy for Frontline Venetoclax Plus Obinutuzumab in CLL?

Othman Al-Sawaf, MDChronic Lymphocytic Leukemia | September 24, 2023

Othman Al-Sawaf, MD, and Nicole Lamanna, MD, debate approaches in this Point | Counterpoint.